You are here: Industry Insights > Market News > News of Note—GlaxoSmithKline’s R&D fix; Leo-HitGen deal; Stanford I-O pact

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

2-Chlorophenothiazine

Flibanserin

its control software

iTS-CTC power cord

iTS-PSMC-24VDC-36VDC-L680-S

iTS-PSC-24VDC-36VDC-L3000-S

News of Note—GlaxoSmithKline’s R&D fix; Leo-HitGen deal; Stanford I-O pact

fiercebiotechAugust 08, 2017

Tag: R&D fix , LEO Pharma , Stanford University

Favorites

> GlaxoSmithKline CEO Emma Walmsley outlined her fix for the company's long-standing pipeline woes. The plan is to give the commercial team a bigger say in pipeline decisions. Article

> Leo Pharma formed a research collaboration with HitGen. The agreement will see HitGen turn its technology on targets of interest to Leo. Statement

> Alligator Bioscience expanded its immuno-oncology collaboration with Stanford University. Release

Previous:Lilly’s novel migraine drug hits PhIII targets

Next:Zynerba sinks after total failure in phase 2 cannabidiol trial

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

PharmaSourcesJuly 04, 2025

InnoCare Pharmaannounced the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794.

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

ACN NewswireJune 20, 2025

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

PR NewswireJune 25, 2025

News of Note—GlaxoSmithKline’s R&D fix; Leo-HitGen deal; Stanford I-O pact | Pharmasources.com

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

ACN NewswireJune 23, 2025

Hua Medicine announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA).

久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

News of Note—GlaxoSmithKline’s R&D fix; Leo-HitGen deal; Stanford I-O pact

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may like
More>>

久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

News of Note—GlaxoSmithKline’s R&D fix; Leo-HitGen deal; Stanford I-O pact

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may likeMore>>

You may like
More>>